Evidence map›Paper›PMID 41209894›Full record

ArticleCureus2025

Major Adverse Cardiovascular Event Outcomes in Patients With Obesity and Type 2 Diabetes Undergoing Medical Weight Management.

Nirjhar Dutta, Katelyn M Tessier, Jenna Langer, Tasma Harindhanavudhi, Shalamar D Sibley, Charles Billington, David Vock, Eric S Wise, Eric M Bomberg, Carolyn Bramante

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nirjhar DuttaDivision of General Internal Medicine, Department of Medicine, University of Minnesota, Minneapolis, USA.
Katelyn M TessierMasonic Cancer Center, Biostatistics Core, University of Minnesota, Minneapolis, USA.
Jenna LangerDivision of General Internal Medicine, Department of Medicine, University of Minnesota, Minneapolis, USA.
Tasma HarindhanavudhiDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Minnesota, Minneapolis, USA.
Shalamar D SibleyDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Minnesota, Minneapolis, USA.
Charles BillingtonDepartment of Endocrinology, Diabetes, and Metabolism, Minneapolis Veterans Affairs Health Care System, Minneapolis, USA.
David VockDivision of Biostatistics, University of Minnesota School of Public Health, Minneapolis, USA.
Eric S WiseDepartment of Surgery, University of Minnesota School of Medicine, Minneapolis, USA.
Eric M BombergDivision of Pediatric Endocrinology, Department of Pediatrics, University of Minnesota Masonic Children's Hospital, Minneapolis, USA.
Carolyn BramanteDivision of Geriatrics, Palliative, and Primary Care, Department of Medicine, University of Minnesota, Minneapolis, USA.

Funding

Precision Medicine Approaches to Obesity Pharmacotherapy in Youth with Severe ObesityK23DK125668 · NIDDK · UNIVERSITY OF MINNESOTA · PI BOMBERG, ERIC MORRIS · 2020 to 2024
$1.0M
NIDDK NIH HHS K23 DK125668
6 · The paper itself

Abstract

objectiveWe assessed the impact of medical weight management (MWM; lifestyle modification ± obesity medications) on major adverse cardiovascular events (MACE) compared to metabolic and bariatric surgery (MBS) and usual care (UC).

methodsWe retrospectively analyzed electronic health records of adults with body mass index (BMI) ≥35 kg/m² and type 2 diabetes mellitus (T2D) at an academic health center from 2010 to 2021. The MWM group was propensity score matched on common confounders 1:1 (versus MBS) and 1:5 (versus UC). The primary outcome was a six-component MACE (all-cause mortality, coronary artery events, cerebrovascular events, heart failure, atrial fibrillation, and nephropathy).  Results: Among 2,100 patients (300 MWM, 300 MBS, and 1,500 UC), baseline characteristics were similar among groups. During a median 3.2-year follow-up (range 0-11), the adjusted hazard ratio (aHR) for MACE for MWM versus MBS was 1.61 (0.98-2.65, p=0.06); for MBS versus UC, aHR 0.66 (0.43-1.02, p=0.06); and there was no difference in MWM versus UC, aHR 1.07 (0.77-1.49, p=0.68).

conclusionsNo statistically significant differences in MACE risk were found between those receiving MWM versus UC; there was a trend towards fewer MACE events in those receiving MBS. These findings must be validated in future studies, given that more effective weight loss medications (e.g., semaglutide, tirzepatide) were not available.

Indexed as

bariatric & metabolic surgerymajor adverse cardiovascular events (mace)multidisciplinary weight managementobesity and diabetesweight management drugs

Identifiers

PMID41209894
PMCPMC12592220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.